Matches in Wikidata for { <http://www.wikidata.org/entity/Q92579699> ?p ?o ?g. }
- Q92579699 description "2019 nî lūn-bûn" @default.
- Q92579699 description "2019年の論文" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年学术文章" @default.
- Q92579699 description "2019年學術文章" @default.
- Q92579699 description "2019年學術文章" @default.
- Q92579699 description "2019年學術文章" @default.
- Q92579699 description "2019年學術文章" @default.
- Q92579699 description "2019年學術文章" @default.
- Q92579699 description "2019년 논문" @default.
- Q92579699 description "article científic" @default.
- Q92579699 description "article scientific" @default.
- Q92579699 description "article scientifique" @default.
- Q92579699 description "articol științific" @default.
- Q92579699 description "articolo scientifico" @default.
- Q92579699 description "artigo científico" @default.
- Q92579699 description "artigo científico" @default.
- Q92579699 description "artigo científico" @default.
- Q92579699 description "artikel ilmiah" @default.
- Q92579699 description "artikull shkencor" @default.
- Q92579699 description "artikulong pang-agham" @default.
- Q92579699 description "artykuł naukowy" @default.
- Q92579699 description "artículo científico publicado en 2019" @default.
- Q92579699 description "artículu científicu" @default.
- Q92579699 description "bilimsel makale" @default.
- Q92579699 description "bài báo khoa học" @default.
- Q92579699 description "naučni članak" @default.
- Q92579699 description "scienca artikolo" @default.
- Q92579699 description "scientific article published on 27 February 2019" @default.
- Q92579699 description "scientific article published on 27 February 2019" @default.
- Q92579699 description "scientific article published on 27 February 2019" @default.
- Q92579699 description "teaduslik artikkel" @default.
- Q92579699 description "tieteellinen artikkeli" @default.
- Q92579699 description "tudományos cikk" @default.
- Q92579699 description "vedecký článok" @default.
- Q92579699 description "vetenskaplig artikel" @default.
- Q92579699 description "videnskabelig artikel udgivet 27. februar 2019" @default.
- Q92579699 description "vitenskapelig artikkel" @default.
- Q92579699 description "vitskapeleg artikkel" @default.
- Q92579699 description "vědecký článek" @default.
- Q92579699 description "wetenschappelijk artikel" @default.
- Q92579699 description "wissenschaftlicher Artikel" @default.
- Q92579699 description "επιστημονικό άρθρο" @default.
- Q92579699 description "мақолаи илмӣ" @default.
- Q92579699 description "наукова стаття, опублікована в лютому 2019" @default.
- Q92579699 description "научна статия" @default.
- Q92579699 description "научная статья" @default.
- Q92579699 description "научни чланак" @default.
- Q92579699 description "научни чланак" @default.
- Q92579699 description "מאמר מדעי" @default.
- Q92579699 description "مقالة علمية نشرت في 27 فبراير 2019" @default.
- Q92579699 description "২৭ ফেব্রুয়ারি ২০১৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q92579699 description "บทความทางวิทยาศาสตร์" @default.
- Q92579699 description "სამეცნიერო სტატია" @default.
- Q92579699 name "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 name "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 type Item @default.
- Q92579699 label "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 label "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 prefLabel "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 prefLabel "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 P1433 Q92579699-CC1F52EA-9F48-491B-9CAA-4E8736B55DDF @default.
- Q92579699 P1476 Q92579699-75CE44F9-FF5C-4461-9CFA-77F9E5158F68 @default.
- Q92579699 P2093 Q92579699-290CC91B-8085-493B-851F-4005A8F5509F @default.
- Q92579699 P2093 Q92579699-4A6CD5E9-9CAD-44D7-BF81-6E53D25D5198 @default.
- Q92579699 P2093 Q92579699-52CC83E2-6EC0-4CCB-ABD8-37F3386E13AB @default.
- Q92579699 P2093 Q92579699-B1F1A6DB-6BA0-4FB4-9F1A-190C9B8BC8D5 @default.
- Q92579699 P2093 Q92579699-B59B3B8C-C09A-4824-9978-B761D91540B1 @default.
- Q92579699 P2093 Q92579699-BA4C6283-8C51-40D4-90A9-CE625638240D @default.
- Q92579699 P304 Q92579699-41BB4B4D-519C-4685-8F5C-12F6EDEC3697 @default.
- Q92579699 P31 Q92579699-F85933C7-9C8F-47A0-B639-6203BCAA2F1A @default.
- Q92579699 P356 Q92579699-7DF040F0-4352-4F9B-A9BB-B3896A33414F @default.
- Q92579699 P433 Q92579699-B4B69C9A-BE3F-4149-8670-AAAF26643556 @default.
- Q92579699 P478 Q92579699-424BAA09-ED98-40A6-A336-C9D676301073 @default.
- Q92579699 P50 Q92579699-280AD2A7-61DF-411E-B2B2-2969F2344896 @default.
- Q92579699 P50 Q92579699-F470936E-221A-439C-9CD0-58812E2B3450 @default.
- Q92579699 P577 Q92579699-2ABC2025-BC01-474F-A0DB-B4269BBC47C0 @default.
- Q92579699 P698 Q92579699-20B7F934-074A-438F-846F-4FE263762D5D @default.
- Q92579699 P921 Q92579699-3C842C0C-6632-4096-A9D1-B239CEF7EA6F @default.
- Q92579699 P921 Q92579699-636D10CA-A449-40BE-A569-D9ECE6938045 @default.
- Q92579699 P921 Q92579699-841737E3-3F9D-40AE-A177-2E18A79CB944 @default.
- Q92579699 P356 J.CLLC.2019.02.016 @default.
- Q92579699 P698 30905617 @default.
- Q92579699 P1433 Q332299 @default.
- Q92579699 P1476 "Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)" @default.
- Q92579699 P2093 "Kenichi Yoshimura" @default.
- Q92579699 P2093 "Koichi Takayama" @default.
- Q92579699 P2093 "Nobuyo Tamiya" @default.
- Q92579699 P2093 "Osamu Hiranuma" @default.
- Q92579699 P2093 "Yoshiko Kaneko" @default.
- Q92579699 P2093 "Yusuke Chihara" @default.
- Q92579699 P304 "e402-e406" @default.
- Q92579699 P31 Q13442814 @default.
- Q92579699 P356 "10.1016/J.CLLC.2019.02.016" @default.
- Q92579699 P433 "3" @default.
- Q92579699 P478 "20" @default.